Publication:
In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH princess maha chakri sirindhorn medical center, srinakharinwirot university and Samitivej Sukhumvit hospital

0
0

Issued Date

2017

Resource Type

Article

File Type

application/pdf

ISSN

1252208

Other identifier(s)

2-s2.0-85019174917

Rights Holder(s)

Scopus

Bibliographic Citation

Journal of the Medical Association of Thailand. Vol 100, No.4 (2017), p.469-478

Suggested Citation

Tantisiriwat W., Linasmita P. In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH princess maha chakri sirindhorn medical center, srinakharinwirot university and Samitivej Sukhumvit hospital. Journal of the Medical Association of Thailand. Vol 100, No.4 (2017), p.469-478. Retrieved from: https://hdl.handle.net/20.500.14740/4187

Title

In vitro activity of sitafloxacin and other antibiotics against bacterial isolates from HRH princess maha chakri sirindhorn medical center, srinakharinwirot university and Samitivej Sukhumvit hospital

Author(s)

Tantisiriwat W.
 Linasmita P.

Abstract

Background: Sitafloxacin is a newly approved oral fluoroquinolone in Thailand for treatment of respiratory tract and urinary tract infections. Initial in vitro susceptibility testing showed its effect on Escherichia coli with extended-spectrum beta-lactamases (ESBL), Klebsiella pneumoniae with ESBL, Pseudomonas aeruginosa, and carbapenem resistant Acinetobacter baumannii. Objective: To retrospectively review in vitro susceptibility to sitafloxacin on clinical isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University (SWU) and Samitivej Sukhumvit Hospital (SVH). Material and Method: Between January 2014 and June 2015, all clinical isolates from SWU and SVH that were added to test in vitro susceptibility to sitafloxacin were included in the present study. The susceptibility for sitafloxacin was identified by disk diffusion method with inhibition zone diameter 19 mm or greater, considered to be sensitive, and smaller than 16 mm considered to be resistance. The comparative activities of sitafloxacin to other antibiotics were determined by organisms. All bacteria with count numbers of more than 30 would be shown in results. Results: Among 1,288 clinical isolates from 1,163 clinical specimens that were added in vitro susceptibility test to sitafloxacin, there were 728 clinical isolates from SWU and 560 clinical isolates from SVH. The most common specimens were sputum (482), urine (385), pus (96), and blood (81). Organisms with comparative activities included E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, and Stenotrophomonas maltophilia. The susceptible percentage of sitafloxacin was 72.69% for all E. coli (n = 216) (68.26% for E. coli with ESBL and 86.96% for E. coli without ESBL), 39.31% for all K. pneumoniae (n = 173) (50% for K. pneumoniae with ESBL, 61.11% for K. pneumoniae without ESBL and 13.11% for carbapenem resistant enterobacteriaceae (CRE) strain of K. pneumoniae), 60.66% for P. aeruginosa (n = 366), 66.32% for A. baumannii (n = 386) and 93.94% for S. maltophilia (n = 33). Sitafloxacin had more susceptible percentage as compared to ciprofloxacin for all strains of E. coli, K. pneumoniae, P. aeruginosa, and A. baumannii and more susceptible percentage as compared to levofloxacin for S. maltophilia. Although sitafloxacin might not have good activity against CRE strain of K. pneumoniae, at least some (13.11%) were susceptible as compared to 0% for ciprofloxacin. Conclusion: Sitafloxacin had more susceptible percentage to E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, and S. maltophilia compared to comparative fluoroquinolones. It should be considered an antibiotic for treatment of respiratory tract and urinary tract infections caused by the resistant strains of these bacteria with susceptible proven of in vitro susceptibility. © 2017, Medical Association of Thailand. All rights reserved.

Subject(s)

Amikacin
 Antiinfective agent
 Ceftriaxone
 Ciprofloxacin
 Colistin
 Ertapenem
 Imipenem
 Levofloxacin
 Sitafloxacin
 Tigecycline
 Acinetobacter baumannii
 Antibacterial activity
 Antibiotic sensitivity
 Article
 Bacterial count
 Bacterium isolate
 Blood culture
 Disk diffusion
 Extended spectrum beta lactamase producing Escherichia coli
 Extended spectrum beta lactamase producing Klebsiella pneumoniae
 Human
 In vitro study
 Inhibition zone
 Major clinical study
 Medical record review
 Minimum inhibitory concentration
 Nonhuman
 Pseudomonas aeruginosa
 Respiratory tract infection
 Sputum culture
 Thailand
 Urinary tract infection
 Urine culture

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/4187

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By